NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1

NCI，国家临床试验网络牵头学术参与站点 (LAPS) UG1

基本信息

批准号：
9914075
负责人：
STEVEN R ALBERTS
金额：
$ 98.4万
依托单位：
MAYO CLINIC ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-04-12 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9914075
关键词：
Advocate American College of Radiology Imaging Network Applications Grants Arizona Awareness Cancer Patient Cancer Science Catchment Area Clinic Clinical Research Clinical Trials Clinical Trials Network Collaborations Conduct Clinical Trials Data Development Discipline Disease Eastern Cooperative Oncology Group Ensure Ethnic Origin Florida Focus Groups Funding Grant Gynecologic Oncology Group Individual Institution International Journals Lead Leadership Malignant Neoplasms Mayo Clinic Cancer Center Mentors Methods Minnesota Minority Minority Enrollment Monitor National Clinical Trials Network National Surgical Adjuvant Breast and Bowel Project North Central Cancer Treatment Group Outcome Participant Patient Care Patients Physicians Population Publications Publishing Research Research Personnel Role Rural Rural Population Site Strategic Planning Underserved Population Universities cancer care cancer clinical trial cancer risk clinical trial enrollment cognitive computing health disparity innovation meetings member named group programs recruit socioeconomics success

项目摘要

PROJECT SUMMARY As reflected in this application, Mayo Clinic has a long tradition of clinical research and has been a supporter and active participant in the National Clinical Trials Network (NCTN). Support of the NCTN includes formation of one of the founding organizations (North Central Cancer Treatment Group, now Alliance), Sustained leadership roles in the NCTN and in clinical trials, as well as active supporters of clinical trials. Multiple Mayo Clinic staff continue in current leadership roles within the NCTN or NCI sponsored activities related to the NCTN. Mayo Clinic remains committed to making NCTN trials a prominent part of its portfolio of clinical trials for cancer patients or patients at-risk for cancer. This commitment is reflected in the prioritization of NCTN trials over many other trials, the level of accrual to NCTN trials, further refinements to the activation and monitoring of progress of NCTN trials to ensure their success, the continued leadership role of Mayo Clinic physicians in the NCTN member organizations, and an on-going commitment of the MCCC to support this activity. Mayo Clinic physicians and researchers continue to have an active role in not only patient accrual to NCTN clinical trials, but to leadership in developing and leading trials. Mayo Clinic researchers also continue to be active in presenting the results of these trials at national and international meetings and high-impact journals, as described within the current grant application. Mayo Clinic researchers have continued to be active in performing subsequent analyses of the collected data, and meaningful use of the biospecimens collected from the trials to transform the science of cancer care. Mayo Clinic has also continued to focus on the development of junior investigators in the NCTN to ensure the continued active support of NCTN member organizations and the success of NCTN clinical research. Finally, Mayo Clinic is committed to making clinical trials available to all patients, regardless of their racial, ethnicity, or socioeconomic background.

项目概要正如本申请所反映的，梅奥诊所拥有悠久的临床研究传统，并一直是其支持者并积极参与国家临床试验网络（NCTN）。 NCTN 的支持包括组建创始组织之一（北中央癌症治疗小组，现为联盟），持续在 NCTN 和临床试验中发挥领导作用，以及临床试验的积极支持者。多个蛋黄酱诊所工作人员继续在 NCTN 或 NCI 赞助的与以下相关的活动中担任当前的领导角色 NCTN。 Mayo Clinic 仍然致力于使 NCTN 试验成为其临床试验组合的重要组成部分对于癌症患者或有癌症风险的患者。这一承诺体现在 NCTN 的优先级上与许多其他试验相比的试验、NCTN 试验的应计水平、对激活和的进一步细化监测 NCTN 试验的进展以确保其成功，梅奥诊所的持续领导作用 NCTN 成员组织的医生以及 MCCC 对此的持续承诺活动。梅奥诊所的医生和研究人员不仅在患者获益方面继续发挥积极作用 NCTN 临床试验，但要在开发和领导试验方面发挥领导作用。梅奥诊所的研究人员还继续积极在国家和国际会议以及高影响力会议上介绍这些试验的结果期刊，如当前拨款申请中所述。梅奥诊所的研究人员继续活跃对收集的数据进行后续分析，并有意义地使用收集的生物样本来自改变癌症治疗科学的试验。梅奥诊所也继续关注 NCTN 初级研究员的发展，以确保 NCTN 成员的持续积极支持组织和 NCTN 临床研究的成功。最后，梅奥诊所致力于使临床所有患者均可参加试验，无论其种族、民族或社会经济背景如何。